Advertisement

Search Results

Advertisement



Your search for ,OUr matches 10724 pages

Showing 2201 - 2250


head and neck cancer

Concurrent Chemoradiation Therapy With Weekly Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma

When combined with radiotherapy as definitive treatment of locally advanced head and neck squamous cell carcinoma, cisplatin at a dose of 40 mg/m2 weekly is noninferior to cisplatin at 100 mg/m2 every 3 weeks, according to the results of the ConCERT trial.1 These findings were presented by Atul...

multiple myeloma

Final Analysis of GRIFFIN Study Presented for Daratumumab-Based Investigational Quadruplet Regimen in Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma

The randomized phase II GRIFFIN study evaluated the investigational use of daratumumab in combination with lenalidomide, bortezomib, and dexamethasone (RVd), followed by maintenance therapy with daratumumab and lenalidomide, compared to RVd followed by maintenance therapy with lenalidomide alone,...

breast cancer

Report Finds 'Batwing' Mastopexy May Enable More Women to Undergo Nipple-Sparing Mastectomy

Nipple-sparing techniques can provide better outcomes for women undergoing breast reconstruction after mastectomy, but due to complication risks, these approaches are often not offered to women with sagging or larger breasts. For this group of patients, a “batwing” incision may provide a safer...

prostate cancer
genomics/genetics

Two New Studies Find Aggressive Prostate Cancer May Be Linked to Ancestral Heritage

Two studies published simultaneously by Jaratlerdsiri et al in Nature and Gong et al in Genome Medicine have identified genetic signatures explaining ethnic differences in the severity of prostate cancer, particularly in sub-Saharan Africa. Through genetic sequencing of prostate cancer tumors from...

head and neck cancer

Can Patients With Low-Risk Nasopharyngeal Cancer Be Treated Safely With Radiotherapy Alone?

Intensity-modulated radiation therapy (IMRT) alone may be considered an effective treatment option for “low-risk” T1–2N1 and T3N0 nasopharyngeal carcinoma, according to trial data presented by Jun Ma, MD, MS, Professor of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China,...

thyroid cancer

Cabozantinib Prolongs Progression-Free Survival in Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer

As reported in The Lancet Oncology by Marcia S. Brose, MD, Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III COSMIC-311 trial has shown that cabozantinib produced a numerically higher objective response rate and significantly prolonged progression-free survival vs...

thyroid cancer
genomics/genetics

Study Finds AI Ultrasound Platform Can Predict Thyroid Malignancy, Pathologic Stage, and BRAF Mutation Status

An artificial intelligence (AI) ultrasound platform that incorporates multiple methods of machine learning can accurately predict thyroid malignancy as well as pathologic and genomic outcomes, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Findings from...

head and neck cancer

De-escalation of Radiation Therapy for HPV-Positive, Intermediate-Risk Oropharyngeal Cancer

De-escalated adjuvant radiotherapy appears to be safe in patients with surgically resectable, human papillomavirus (HPV)--positive oropharyngeal cancers, particularly in patients without extranodal extension or pN2 disease by American Joint Committee on Cancer (AJCC) 8th edition. These findings...

head and neck cancer

Midtreatment Imaging De-escalates Therapy for Half of Study Patients With Oropharyngeal Cancer

Positron-emission tomography (PET) scans obtained before and midway through treatment may be used to de-escalate therapy for patients with oropharyngeal cancer, leading to fewer side effects, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 An interim...

head and neck cancer

Are Disadvantaged Patients Less Likely to Receive Advanced Radiotherapy Techniques for Head and Neck Cancer?

Advanced radiotherapy techniques may reduce the risk of severe and debilitating toxicity associated with radiation, but not all patients have equal access to these modalities, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Retrospective analysis of the...

head and neck cancer

Head and Neck Cancer 2021–2022 Almanac

Head and neck cancer is the seventh most common cancer in the world, with 1.1 million new diagnoses reported annually.1 In the United States, the incidence of oral and pharyngeal cancers is over 54,000 cases per year, resulting in over 11,000 yearly deaths.2 Although smoking and alcohol consumption ...

issues in oncology

Researchers Outline a Path to Representation in Cancer Clinical Trials

A new study published by Birhiray et al in Blood Advances outlines practical strategies for promoting diversity, equity, inclusion, and access in cancer clinical research. The study highlights significant racial disparities in cancer research, citing that between 2008 and 2018, only 7.8% of...

lung cancer

Deep-Learning Algorithm May Streamline Lung Cancer Radiotherapy Treatment

Lung cancer, the most common cancer worldwide, is targeted with radiation therapy in nearly one-half of cases. Radiation therapy planning is a manual, resource-intensive process that can take days to weeks to complete, and even highly trained physicians vary in their determinations of how much...

breast cancer
genomics/genetics

Researchers Identify Markers of Chemotherapy Resistance and Outcome in Patients With Triple-Negative Breast Cancer

Researchers have identified biological markers in patients with triple-negative breast cancer that are associated with resistance to chemotherapy. The study was published by Anurag et al in the journal Cancer Discovery and was funded by the National Cancer Institute’s Clinical Proteomics Tumor...

global cancer care

Clinical and Translational Researcher Rossana Berardi, MD, Works to Overcome the Gender Gap in Oncology in Italy

In our continuing effort to connect and learn more about our international oncology colleagues, The ASCO Post recently spoke with Rossana Berardi, MD, Professor in Medical Oncology and Director of the Postgraduate School of Oncology at the Università Politecnica Marche, Ancona, Italy, where she is...

lung cancer
global cancer care

International Career Joins Cancer Research and Clinical Care of Patients With Lung Cancer

Pilar Garrido, MD, PhD, is Head of the Medical Oncology Department, University Hospital Ramón y Cajal, Madrid. She is also Co-Director of the Cancer Research Group at Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Her main areas of research and clinical interest are thoracic tumors,...

prostate cancer

MRI-Guided Ultrasound Focal Therapy May Delay or Avoid Prostatectomy or Radiotherapy in Patients With Intermediate-Risk Prostate Cancer

MRI-guided focused ultrasound focal therapy produced “a high degree of success” and “a low rate of genitourinary adverse events” when used to treat select patients with intermediate-grade prostate cancer, Behfar Ehdaie, MD, MPH, and colleagues reported in The Lancet Oncology.1 Dr. Ehdaie is...

An Oncologist and His Patient With Cancer Look at the Intimate Experience of Life and Death

"This e-mail is different from my usual. No smiley faces or funny cartoons, for I have moved on to another location…. My place in the long line of life has suddenly been jumped up to the head of the queue, and now I have a boarding pass,” notes Harry, a patient with end-stage lung cancer who has...

prostate cancer

Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up

Radiotherapy to the prostate in addition to standard treatment may improve survival for some men with advanced prostate cancer without detriment to quality of life, long-term study results from the STAMPEDE trial confirmed. These findings were published by Chris C. Parker, MD, and colleagues in...

covid-19
survivorship

How Did the First Year of the COVID-19 Pandemic Affect Cancer Survivors?

Recent research published by Xuesong Han, PhD, and colleagues in the journal Cancer indicated that during the first year of the COVID-19 pandemic, the proportion of working-aged U.S. adults without health insurance did not change despite increases in unemployment. The prevalence of unhealthy...

supportive care
palliative care

Study Examines Effects of Advance Care Planning for Adolescents With Cancer

In a recently published study by Needle et al in JAMA Network Open, University of Minnesota researchers and colleagues say adolescents with cancer deserve a voice in medical decisions made for and about them.  “Adolescents with cancer should be given the opportunity to participate in their own...

leukemia

Proximity to Fracking Sites May Be Associated With Risk of Pediatric Leukemia

Children in Pennsylvania living near unconventional oil and gas developments at birth were two to three times more likely to be diagnosed with leukemia between the ages of 2 and 7 years than children who did not live near this oil and gas activity, after accounting for other factors that could...

breast cancer
survivorship
supportive care

Cancer-Related Fatigue Linked to Balance Problems After Chemotherapy for Breast Cancer

For many patients who have received chemotherapy for breast cancer, cancer-related fatigue is a persistent side effect—and one that contributes to ongoing balance problems, suggests a recent paper published by Weschler et al in Rehabilitation Oncology. The new research by Stephen Wechsler, PT, DPT, ...

lymphoma

Rituximab, Lenalidomide, and Ibrutinib With Sequential Addition of Chemotherapy in Newly Diagnosed DLBCL: Smart Start Trial

In a single-institution phase II trial (Smart Start) reported in the Journal of Clinical Oncology, Jason Westin, MD, MS, and colleagues found that initiating treatment with rituximab, lenalidomide, and ibrutinib (RLI) followed by the sequential addition of chemotherapy resulted in high response...

issues in oncology

Nine Oncology Practices Certified Through ASCO Patient-Centered Cancer Care Certification Pilot

ASCO recently announced that nine outpatient oncology group practices have achieved certification through the new ASCO Patient-Centered Cancer Care Certification pilot based on their adherence to oncology medical home (OMH) standards, a single set of comprehensive, expert-backed standards for...

lung cancer

New Guideline Updates Address Stage IV Non–Small Cell Lung Cancer With and Without Driver Alterations

Two ASCO guideline updates provide new evidence-based recommendations for the systemic treatment of stage IV non–small cell lung cancer (NSCLC) with and without driver alterations.1,2 Among several other updates, these new guidelines add the ALK and ROS1 inhibitor lorlatinib and the PD-L1 immune...

Anthony S. Fauci, MD, to Step Down From Current Roles in December

Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases (NIAID), announced his intention to step down from his various roles in December 2022. He issued the following statement on August 22: I am announcing today that I will be stepping down from the positions...

breast cancer

APHINITY Trial in Patients With HER2-Positive Early Breast Cancer: Update at 8 Years

Updated results from the adjuvant APHINITY trial in HER2-positive early breast cancer, now with a median follow-up of 8.4 years, confirmed the benefit of adding pertuzumab to trastuzumab plus chemotherapy in preventing invasive disease recurrences, but as yet no statistically significant overall...

skin cancer

Study Evaluates UV Protective Behaviors in American Indian and Alaskan Native Populations

Ultraviolet (UV) protection from the sun and avoiding indoor tanning play important roles in reducing a person’s risk for skin cancer, the most common cancer in the United States and one of the most preventable. A recent article published by Yang et al in the Journal of the American Academy of...

immunotherapy
supportive care

Stem Cell Boost as Salvage Therapy for Severe Hematologic Toxicity After CD19 CAR T-Cell Therapy

In a retrospective study reported in a research letter in Blood Advances, Rejeski et al found that a stem cell boost was successful in treating severe hematologic toxicity in patients who had received CD19 chimeric antigen receptor (CAR) T-cell therapy for refractory B-cell malignancies. Study...

pancreatic cancer

Sequencing Therapies May Improve Overall Survival in Metastatic Pancreatic Cancer

In the first-line treatment of metastatic pancreatic cancer, the sequencing of nab-paclitaxel plus gemcitabine with FOLFOX (fluorouracil, leucovorin, oxaliplatin) resulted in a significant improvement in overall survival at 12 months and in all other efficacy endpoints as compared with the standard ...

solid tumors

Snapshots of Studies of Interest Presented at ASCO 2022

The 2022 ASCO Annual Meeting was filled with important science, engaging data, and several practice-changing abstracts, many of which have been covered in detail on other pages or in earlier issues of The ASCO Post. There were numerous high-impact studies and attendees, whether present at the...

issues in oncology

Impact of the Dobbs v Jackson Women’s Health Organization Ruling on Patients With Cancer

As a nonpartisan organization, the American Cancer Society has an overarching goal to improve the lives of patients with cancer and their families. We believe all individuals should have an equitable opportunity to prevent, find, detect, and survive cancer, irrespective of geography. The June 24...

multiple myeloma

Is Science Getting Closer to Preventing Multiple Myeloma?

About 3 years ago, researchers from Dana-Farber Cancer Institute launched PROMISE (Predicting Progression of Developing Myeloma in a High-Risk Screen Population; ClinicalTrials.gov identifier NCT03689595), a large, ambitious screening study to identify individuals at high risk of developing...

genomics/genetics

PREMMplus Tool May Assist in Identifying People Likely to Benefit From Multigene Hereditary Cancer Risk Assessment

An online tool developed by researchers and physicians at Dana-Farber Cancer Institute may accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing certain cancers, according to findings reported by Yurgelun et al in the...

colorectal cancer

Study Tests Strategy for Reducing Colorectal Cancer Risk Among Patients With Familial Adenomatous Polyposis

Researchers from the Mayo Clinic Comprehensive Cancer Center and the Mayo Clinic Center for Individualized Medicine are studying the rare genetic condition called familial adenomatous polyposis, looking for potential ways to prevent colorectal cancer in the general population at an earlier, more...

palliative care

Is Advance Care Planning of Any Value?

An article in The New York Times earlier this year crystallized the dilemma facing health-care providers when they are presented with a patient in a life-threatening situation: Should they rely on advance care directives written years prior to the current medical situation to accurately determine...

hepatobiliary cancer

Does Exposure to 'Forever Chemical' Elevate Risk of Developing Hepatocellular Carcinoma?

Exposure to a synthetic chemical found widely in the environment may be linked to the development of nonviral hepatocellular carcinoma, according to a new study published by Goodrich et al in JHEP Reports. The chemical—called perfluorooctane sulfate, or PFOS—is one of a class of man-made chemicals...

lung cancer

Study Shows Germline Testing May Be Warranted for All Patients With Lung Cancer

Germline testing may be warranted for all patients with lung cancer, according to research presented by Sorscher et al during the August ASCO Plenary Series Program (Abstract 388570). The retrospective review of nearly 8,000 patients with lung cancer undergoing germline testing found that 14.9% had ...

lymphoma
genomics/genetics

Study Reveals Potential Genomic Contributors to the Development of DLBCL

By searching previously ignored regions of the genome, researchers have found a multitude of new genetic mutations that may contribute to diffuse large B-cell lymphoma (DLBCL). These findings were published by Bal et al in Nature. “Our findings not only show that these mutations can contribute to...

global cancer care

A Surgical Oncologist From Afghanistan Discusses the Challenges of Delivering Cancer Care in a War-Torn Nation

In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Ahmad Bashir Barekzai, MD, FACS, Consultant Surgical Oncologist at Ali Abad Teaching Hospital, an affiliated hospital to Kabul University of Medical Science, Kabul,...

hematologic malignancies
geriatric oncology

Relationship Between Polypharmacy and Frailty Among Older Adults With Blood Cancers

A new study published by Hshieh et al in JNCCN–Journal of the National Comprehensive Cancer Network suggests a new way for hematologic oncologists to protect older patients from the risks of medication interactions. As part of the Older Adult Hematologic Malignancies Program, gerontology...

leukemia
genomics/genetics

Molecular Map Reveals Insights Into the Genetic Drivers of CLL

A newly constructed map of the landscape of genetic changes in chronic lymphocytic leukemia (CLL) may provide a better understanding of this complex malignancy, which could lead to more accurate prognoses for patients, improved diagnostics, and novel treatments. These research findings were...

leukemia
immunotherapy

Higher Doses of CAR T-Cell Therapy May Improve Survival for Young Patients With B-Cell ALL

Young people with B-cell acute lymphoblastic leukemia (ALL) who received doses of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, at the higher end of the approved dosing range had significantly better survival rates at 1 year compared with those who received lower doses within...

breast cancer

Locoregional Recurrence With Predefined Risk-Based De-escalation of Radiotherapy After Primary Chemotherapy in cT1–2N1 Breast Cancer

As reported in The Lancet Oncology by de Wild et al, 5-year follow-up from a Dutch prospective registry study (RAPCHEM, BOOG 2010-03) showed low rates of locoregional recurrence with de-escalation of adjuvant radiotherapy according to predefined risk levels in women receiving primary chemotherapy...

lung cancer

Informed Consent Forms for Lung Cancer Clinical Trials May Be a Barrier to Informed Participation

Informed consent forms can be overwhelming for patients—they are written at a level that is too high for many patients, possibly impeding true informed consent, according to a report given by King-Kallimanis et al at the International Association for the Study of Lung Cancer (IASLC) 2022 World...

lung cancer

Research Suggests Air Pollution Be Included as Risk Factor for Nonsmoking Patients With Lung Cancer

Researchers from Vancouver, British Columbia examined the effect of duration of past exposure to air pollution with lung cancer diagnosis in new research presented by Myers et al at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2022 (Abstract...

solid tumors

Thriving After a Diagnosis of Stage II Anal Cancer

About 7 years ago, I had emergency hernia surgery and soon after began experiencing severe constipation and abdominal bloating. I had started to have minor symptoms leading up to the surgery, but now the pain and exhaustion of trying to have a bowel movement became unbearable. I met with a...

Dana-Farber’s Irene Ghobrial, MD, Selected as William Dameshek Prize Winner

Irene Ghobrial, MD, Director of the Clinical Investigator Research Program at Dana-Farber Cancer Institute, Boston, has received the William Dameshek Prize. This award is given annually by the American Society of Hematology (ASH) to an individual younger than age 50 who has made outstanding...

His Grandmother’s Death Inspires a Career in Oncology for Manmeet S. Ahluwalia, MD, MBA

In this installment of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Manmeet S. Ahluwalia, MD, MBA, Deputy Director, Chief Scientific Officer, and Chief of Solid Tumor Medical Oncology at Miami Cancer Institute, where his research focuses on the development of new therapies for...

Advertisement

Advertisement




Advertisement